Inclusion Criteria:

- At least 18 years of age

- Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma proven
by histology or cytology and previously untreated with chemotherapy or systemic
therapy other than:

- Radiosensitizing doses of 5-fluorouracil;

- Radiosensitizing doses of gemcitabine if relapse occurred at least 6 months
after completion of gemcitabine;

- Neoadjuvant chemotherapy if relapse occurred at least 6 months after surgical
resection;

- Adjuvant chemotherapy if relapse occurred at least 6 months after completion of
adjuvant chemotherapy

- Measurable disease (at least one target lesion outside of previous radiation fields)
or non-measurable disease by RECIST v.1.1 criteria

- Documentation of disease progression since any prior therapy

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

- Life expectancy of at least 3 month

- Acceptable liver, renal function and acceptable hematological status

- Other protocol defined inclusion criteria may apply

Exclusion Criteria:

- New York Heart Association (NYHA) Class III or IV congestive heart failure,
myocardial infarction within 6 months prior to the date of randomization, unstable
arrhythmia or symptomatic peripheral arterial vascular disease

- Symptomatic ischemic heart disease

- Known brain, leptomeningeal or epidural metastases (unless treated and well
controlled for at least 3 months)

- Previous malignancy other than pancreatic cancer in the last 5 years, except for
adequately treated non-melanoma skin cancer or pre-invasive cancer of the cervix

- Severe chronic obstructive or other pulmonary disease with hypoxemia

- Major surgery, other than diagnostic surgery, less than or equal to 28 days prior to
the date of randomization. Subject must have completely recovered from surgery

- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
therapy

- Treatment of pancreatic cancer with radiation therapy or surgery less than or equal
to 28 days prior to the date of randomization

- Prior therapy with a hypoxic cytotoxin

- Subjects who participated in an investigational drug or device trial less than or
equal to 28 days prior to Day 1 of the first cycle

- Known infection with Human Immunodeficiency Virus (HIV), or an active infection with
Hepatitis B or Hepatitis C

- Subjects who have exhibited allergic reactions to a structural compound similar to
TH-302 or the drug product excipients or to gemcitabine or its excipients

- Other protocol defined exclusion criteria may apply